Allopurinol

규격

315-30-0CAS 번호

206-250-9EC 번호

1,5-dihydropyrazolo[5,4-d]pyrimidin-4-oneIUPAC 명칭

C5H4N4O화학식

136.11 g/mol분자량

allopurinol; 315-30-0; 1H-Pyrazolo[3,4-d]pyrimidin-4-ol; Zyloric; Suspendol; Takanarumin; Allopur; Bloxanth; Uriprim; Xanturat; Urbol; Ketobun-A; Nektrohan; Adenock; Aluline; Dabrosin; Urobenyl; 4-Hydroxypyrazolo[3,4-d]pyrimidine; 1,5-Dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one; Allopurinol(I); Allopurinolum; 4-HPP; Alopurinol; 1H-Pyrazolo(3,4-d)pyrimidin-4-ol; 4-Hydroxypyrazolopyrimidine; NSC-1390; 4-Hydroxy-1H-pyrazolo(3,4-d)pyrimidine; 4-Hydroxy-3,4-pyrazolopyrimidine; Sigapurol; 4-Hydroxypyrazolo(3,4-d)pyrimidine; 4-Hydroxypyrazolyl(3,4-d)pyrimidine; 4H-Pyrazolo(3,4-d)pyrimidin-4-one; 4'-Hydroxypyrazolol(3,4-d)pyrimidine; BW 56-158; AL-100; BW-56-158; 1,5-Dihydro-4H-pyrazolo(3,4-d)pyrimidin-4-one; 1,5-Dihydropyrazolo[3,4-d]pyrimidin-4-one; 1,5-Dihydro-4H-pyrazolo(3,4-d)pyrimidine-4-one; Uricto; DTXSID4022573; CHEBI:40279; 4H-Pyrazolo(3,4-d)pyrimidin-4-one, 1,5-dihydro-; 4H-Pyrazolo[3,4-d]pyrimidin-4-one, 1,5-dihydro-; 1,2-dihydropyrazolo[3,4-d]pyrimidin-4-one; 63CZ7GJN5I; Xanthomax-100; Xanthomax-300; NSC-101655; Aluline 100; Aluline 300; Hamarin 100; Hamarin 300; Zyloric-300; NSC1390; 1H,2H,4H-pyrazolo[3,4-d]pyrimidin-4-one; NSC101655; BW-56158; 4-Hydroxy-1H-pyrazolo[3,4-d]pyrimidine; DTXCID502573; DUZALLO COMPONENT ALLOPURINOL; Milurite; Allohexan; 4-Hydroxypyrazolyl[3,4-d]pyrimidine; Pan Quimica; 4'-Hydroxypyrazolol[3,4-d]pyrimidine; 1,2-dihydropyrazolo(3,4-d)pyrimidin-4-one; 1,5-dihydropyrazolo(3,4-d)pyrimidin-4-one; 1H,2H,4H-pyrazolo(3,4-d)pyrimidin-4-one; allopurinolo; Zurinol; RefChem:54100; 4'-HPP; M04AA01; 1,5-Dihydro-4H-pyrazolo(3,4-d)pryimidin-4-one; 206-250-9; Zyloprim; Lopurin; Urosin; Atisuril; Epidropal; Uricemil; Anzief; Urolit; Anoprolin; Miniplanor; Ailural; Allozym; Alositol; Cosuric; Gichtex; Ledopur; Progout; Aloral; Apurol; Riball; 1H-Pyrazolo[3,4-d]pyrimidin-4(5H)-one; Ketanrift; Monarch; Hexanuret; Epuric; 180749-06-8; 180749-08-0; 73334-58-4; Dura Al; 1H-pyrazolo[3,4-d]pyrimidin-4(7H)-one; 2H-Pyrazolo[3,4-d]pyrimidin-4-ol; Urtias 100; Alopurinol [INN-Spanish]; Allopurinolum [INN-Latin]; 1H-pyrazolo[3,4-d]pyrimidin-4(2H)-one; 180749-09-1; 916980-04-6; MFCD00599413; Zyloprim (TN); 1H,4H,7H-pyrazolo[3,4-d]pyrimidin-4-one; B. W. 56-158; 4H-Pyrazolo[3,4-d]pyrimidin-4-one, 1,2-dihydro-; 180749-07-9; 184789-03-5; MLS000069453; SMR000059083; 291279-53-3; 1H,4H,5H-pyrazolo[3,4-d]pyrimidin-4-one; 4-Oxopyrazolo[3,4-d]pyrimidine; NCGC00015094-02; NCGC00094580-04; Uritas; 1,5-Dihydro-pyrazolo[3,4-d]pyrimidin-4-one; 1,7-Dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one; 4H-pyrazolo[3,4-d]pyrimidin-4-one, 1,7-dihydro-; F3329-0375; NSC 1390; pyrazolo[5,4-d]pyrimidin-4-ol; 4H-Pyrazolo[3, 1,5-dihydro-; Ailurial; WLN: T56 BMN GN INJ FQ; CAS-315-30-0; CCRIS 626; NSC 101655; HSDB 3004; SR-05000001983; EINECS 206-250-9; UNII-63CZ7GJN5I; Allohexal;; ATH008; Allopurinol RS; Zyloprim;; 1H-Pyrazolo[3,4-d]pyrimidin-4-ol (9CI); Allopurinol CRS; Allosig;; Progout;; 4H-Pyrazolo[3,4-d]pyrimidin-4-one, 1,7-dihydro- (9CI); Xanthione oxidase; Prestwick_511; Allopurinol [USAN:USP:INN:BAN:JAN]; Allopurinol (Standard); Spectrum_000026; 4H-Pyrazolo[3,4-d]pyrimidin-4-one, 2,5-dihydro- (9CI); 4H-Pyrazolo[3,4-d]pyrimidin-4-one, 2,7-dihydro- (9CI); Allopurinol - EP grade; ALLOPURINOL [MI]; Opera_ID_1680; Spectrum2_000098; Spectrum3_000289; Spectrum4_000135; Spectrum5_000768; ALLOPURINOL [INN]; ALLOPURINOL [JAN]; Lopac-A-8003; 1,4-d]pyrimidin-4-one; ALLOPURINOL [HSDB]; ALLOPURINOL [USAN]; Epitope ID:226980; A 8003; cid_2094; SCHEMBL4627; SCHEMBL4628; A1BD4; ALLOPURINOL [MART.]; CHEMBL1467; NCIOpen2_001825; Lopac0_000102; SCHEMBL25803; ALLOPURINOL [USP-RS]; ALLOPURINOL [WHO-DD]; ALLOPURINOL [WHO-IP]; BSPBio_001798; KBioGR_000550; KBioSS_000386; MLS001148183; US9138393, Allopurinol; US9144538, Allopurinol; DivK1c_000685; SCHEMBL167561; SCHEMBL626453; SPECTRUM1500108; SPBio_000056; ALLOPURINOLUM [WHO-IP]; GTPL6795; orb1225329; orb1310380; orb3025936; SCHEMBL1128219; SCHEMBL3739112; SCHEMBL5550199; SCHEMBL6034419; SCHEMBL7400319; SCHEMBL7400321; SCHEMBL7403740; Allopurinol (JP18/USP/INN); SCHEMBL28672687; SCHEMBL29693720; BDBM35440; HMS502C07; HY-B0219R; KBio1_000685; KBio2_000386; KBio2_002954; KBio2_005522; KBio3_001298; ALLOPURINOL [EP IMPURITY]; ALLOPURINOL [ORANGE BOOK]; NINDS_000685; ALLOPURINOL [EP MONOGRAPH]; BDBM181133; GLXC-07785; HMS1920A15; HMS2091G15; HMS2234M09; HMS3259K13; HMS3260E06; HMS3371I11; HMS3651O13; HMS3714L22; HMS5079O22; Pharmakon1600-01500108; ALLOPURINOL [USP MONOGRAPH]; SMSSF-0109038; HY-B0219; MSK10865; STR05189; Tox21_110082; Tox21_200922; Tox21_500102; 4-Hydroxy-pyrazolo[3,4-d]pyrimidin; AC-019; BBL009959; BDBM50016784; BDBM50140241; CCG-38916; EBC-03149; MFCD08276167; NSC755858; s1630; SBB004202; SC1118; SC2251; STK378584; STK711106; 1,2,5,7-tetraaza-5H-inden-4-ol; AKOS000267490; AKOS000269759; AKOS024255717; Tox21_110082_1; Allopurinol, xanthine oxidase inhibitor; CCG-204197; CCG-221406; CCG-266128; DB00437; FA17288; LP00102; NC00492; NSC-755858; SB10164; SDCCGSBI-0050090.P005; IDI1_000685; NCGC00015094-01; NCGC00015094-03; NCGC00015094-04; NCGC00015094-05; NCGC00015094-06; NCGC00015094-07; NCGC00015094-08; NCGC00015094-18; NCGC00015094-21; NCGC00015094-22; NCGC00091134-01; NCGC00091134-02; NCGC00091134-03; NCGC00094580-01; NCGC00094580-02; NCGC00094580-05; NCGC00188948-01; NCGC00258476-01; NCGC00260787-01; FA160361; FA162226; TS-00028; SBI-0050090.P004; DB-065332; DB-261136; DB-272461; DB-272465; DB-272466; DB-272469; A0907; A4445; EU-0100102; NS00000618; ST45179105; SW199406-4; T0692; 1,5-dihydropyrazolo[3,4-d]-pyrimidin-4-one; EN300-34144; VU0611037-1; BIM-0061756.0001; D00224; F18007; 1,5Dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one; AB00173448-03; AB00173448-04; AB00173448_05; AB01274719-01; AB01274719_02; AB-323/25048497; F069190; Q412486; SR-01000075595; 4H-Pyrazolo[3,4-d]pyrimidin-4-one, 2,5-dihydro-; SR-01000075595-1; SR-05000001983-1; SR-05000001983-2; BRD-K86307448-001-16-7; BRD-K86307448-001-17-5; BRD-K86307448-001-19-1; F2173-0394; Z104486670; 4H-Pyrazolo[3,4-d]pyrimidin-4-one, 1,2-dihydro- (9CI); 4H-PYRAZOLO[3,4-D]PYRIMIDIN-4-ONE, 2,7-DIHYDRO-; Allopurinol, British Pharmacopoeia (BP) Reference Standard; Allopurinol, European Pharmacopoeia (EP) Reference Standard; Allopurinol, United States Pharmacopeia (USP) Reference Standard; 1,5-Dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one Synonym: Allopurinol; Allopurinol, Pharmaceutical Secondary Standard; Certified Reference Material; InChI=1/C5H4N4O/c10-5-3-1-8-9-4(3)6-2-7-5/h1-2H,(H2,6,7,8,9,10; 691008-24-9; allopurinol, Zyloprim, Zyloric, Lopurin, Milurit, Progout, Atisuril, Bleminol, Uripurinol, Embarin, Foligan, Urosin, 1H-Pyrazolo[3,4-d]pyrimidin-4-ol, 315-30-0, Alositol, Anoprolin, Apulonga, Bloxanth, Caplenal, Cellidrin동의어